A randomized, parallel-group, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Vilaprisan (Primary) ; Ulipristal
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms ASTEROID 5
- Sponsors Bayer
- 27 Aug 2019 Planned End Date changed from 16 Sep 2021 to 12 Feb 2022.
- 27 Aug 2019 Planned primary completion date changed from 16 Sep 2021 to 12 Feb 2022.
- 23 Mar 2019 This trial was suspended in Portugal, according to European Clinical Trials Database.